Lung cancer: Defining standard of care for performance status 2--don't rush
- PMID: 23881037
- DOI: 10.1038/nrclinonc.2013.134
Lung cancer: Defining standard of care for performance status 2--don't rush
Abstract
The standard treatment for patients with advanced-stage non-small-cell lung cancer with a performance status of 2 is unclear because of the heterogeneity of this population. Although a recent trial suggests that carboplatin plus pemetrexed improves survival as compared to single-agent pemetrexed, we should be cautious when defining new standards of treatment on the basis of single small trials.
Comment on
-
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2012 Oct;23 Suppl 7:vii56-64. doi: 10.1093/annonc/mds226. Ann Oncol. 2012. PMID: 22997455 No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical